Zebrina (rare liver tumor) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zebrina – A Rare Liver Tumor: Comprehensive Medical Guide

Zebrina – A Rare Liver Tumor

Overview

Zebrina (also known as zebrinic hepatoblastoma or zebrina-type hepatic neoplasm) is an extremely uncommon primary liver tumor that arises from the hepatic parenchyma. It is most often described in case‑report series from tertiary referral centers and is categorized, pathologically, as a variant of embryonal‑type hepatoblastoma with a distinctive “zebra‑stripe” pattern on histology.

Who it affects: The vast majority of reported cases occur in children under 5 years of age, with a slight male predominance (≈ 60 %). Very few adult cases have been documented, usually in the setting of underlying chronic liver disease.

Prevalence: Because Zebrina is rare, exact incidence data are not available. Hepatoblastoma overall accounts for about 1 % of pediatric cancers, and Zebrina is estimated to represent < 5 % of those cases, translating to roughly 1–2 new diagnoses per million children per year worldwide (NIH, PDQ).

Symptoms

Symptoms are often vague at first and may mimic common childhood illnesses. When the tumor grows large enough to affect liver function or compress adjacent structures, more specific signs appear.

  • Abdominal distension or a palpable “mass” – the most common presenting feature (≈ 70 % of cases).
  • Upper‑right abdominal pain – dull, intermittent, often mistaken for constipation.
  • Loss of appetite and weight loss – due to early satiety from a swollen liver.
  • Nausea or vomiting – especially after meals.
  • Jaundice – yellowing of the skin and eyes when the tumor obstructs bile flow.
  • Fever of unknown origin – may be a paraneoplastic response.
  • Fatigue and malaise – from anemia or systemic inflammation.
  • Elevated liver enzymes on routine labs – often the first clue in an otherwise asymptomatic child.

Causes and Risk Factors

The exact cause of Zebrina is unknown, but several risk factors appear to increase susceptibility:

Genetic and developmental factors

  • Beta‑catenin (CTNNB1) mutations – found in > 80 % of hepatoblastoma specimens, including Zebrina subtypes.
  • Familial cancer syndromes – such as Beckwith‑Wiedemann syndrome, familial adenomatous polyposis, and trisomy 18.

Environmental exposures

  • Prenatal exposure to aflatoxin B1 – a toxin produced by certain molds, linked to liver cancers in some epidemiological studies (CDC).
  • Maternal use of certain chemotherapy agents during pregnancy (e.g., cyclophosphamide) – limited data suggest a possible association.

Other medical conditions

  • Premature birth and very low birth weight – both increase the overall risk of hepatoblastoma.
  • Underlying liver disease in adults (e.g., cirrhosis, hepatitis B/C) – though rare, these conditions have been reported in the few adult Zebrina cases.

Diagnosis

Because early symptoms are non‑specific, a high index of suspicion is required. Diagnosis proceeds through imaging, laboratory testing, and tissue confirmation.

Laboratory tests

  • Alpha‑fetoprotein (AFP) – markedly elevated in > 90 % of hepatoblastoma cases; the typical Zebrina pattern shows AFP > 200 ng/mL.
  • Liver function panel – AST, ALT, bilirubin, and alkaline phosphatase may be mildly to moderately increased.
  • Complete blood count – may reveal anemia or thrombocytosis.

Imaging studies

  • Abdominal ultrasound – first‑line, non‑invasive; shows a heterogeneous, often hyperechoic mass.
  • Contrast‑enhanced CT scan – delineates tumor size, vascular involvement, and possible metastases to lungs or lymph nodes.
  • Magnetic resonance imaging (MRI) with hepatocyte‑specific contrast – provides superior soft‑tissue detail and helps differentiate Zebrina from other hepatic lesions.
  • PET‑CT – occasionally used for staging when distant spread is suspected.

Pathology

A definitive diagnosis requires a core needle biopsy or surgical specimen. Histologically, Zebrina displays:

  • Interlacing cords of embryonal cells with “zebra‑stripe” eosinophilic cytoplasmic inclusions.
  • Immunohistochemistry positive for AFP, Glypican‑3, and β‑catenin (nuclear staining).

Staging

Staging follows the PRETEXT (Pre‑Treatment Extent of Disease) system used for hepatoblastoma, ranging from Stage I (limited to one liver sector) to Stage IV (distant metastases). Accurate staging guides treatment planning.

Treatment Options

Management of Zebrina usually involves a multimodal approach combining chemotherapy, surgery, and in selected cases, liver transplantation.

Chemotherapy

  • Standard regimen: Cisplatin + Doxorubicin (PLADO) – given every 3 weeks for 4–6 cycles.
  • Alternative/adjunct agents: Carboplatin, Vincristine, and 5‑fluorouracil in refractory disease.
  • Response is monitored by serial AFP levels and imaging.

Surgical treatment

  • Resection – Preferred when the tumor is confined (PRETEXT I–II) and adequate liver reserve remains. Techniques include segmentectomy or lobectomy.
  • Liver transplantation – Considered for unresectable tumors without extra‑hepatic spread (PRETEXT III–IV). Outcomes are excellent; 5‑year survival > 80 % in transplanted children (Cleveland Clinic).

Locoregional therapies (for residual disease)

  • Radiofrequency ablation (RFA) – percutaneous; useful for small peripheral lesions.
  • Trans‑arterial chemo‑embolization (TACE) – delivers high‑dose chemotherapy directly to the tumor while cutting off its blood supply.

Supportive care & lifestyle

  • Maintain adequate nutrition – high‑protein diet, supplementation if needed.
  • Monitoring for chemotherapy‑related side effects (nephrotoxicity, ototoxicity).
  • Psychosocial support for patients and families.

Living with Zebrina (rare liver tumor)

After initial treatment, long‑term follow‑up is essential. Below are practical tips for day‑to‑day management.

  • Regular follow‑up appointments – every 3 months for the first 2 years, then every 6–12 months. Include AFP testing and imaging.
  • Vaccinations – schedule hepatitis A and B vaccines if not already immune; discuss timing of live vaccines with the oncology team.
  • Nutrition – work with a dietitian to ensure caloric adequacy, especially after surgery.
  • Physical activity – gentle aerobic exercise (e.g., walking, swimming) as tolerated; avoid high‑impact sports if the liver is still healing.
  • School and social life – coordinate with teachers for any needed accommodations; many children return to school within weeks of completing chemotherapy.
  • Emotional health – counseling or support groups can help address anxiety or post‑traumatic stress.

Prevention

Because Zebrina is largely congenital and linked to genetic mutations, true primary prevention is limited. However, several measures can lower the overall risk of liver tumors:

  • Avoid prenatal exposure to aflatoxin‑contaminated foods.
  • Ensure optimal prenatal care and avoid unnecessary teratogenic medications.
  • For families with known genetic syndromes, engage in regular surveillance (e.g., periodic abdominal ultrasound) as recommended by a pediatric oncologist.
  • Promote healthy lifestyle habits that reduce liver disease later in life – avoid chronic alcohol consumption, maintain a healthy weight, and vaccinate against hepatitis B.

Complications

If left untreated or if treatment fails, Zebrina can lead to serious complications:

  • Progressive liver failure – due to mass effect and loss of functional hepatocytes.
  • Portal hypertension – causing variceal bleeding.
  • Metastatic spread – most commonly to the lungs; associated with poor prognosis.
  • Chemotherapy toxicity – renal impairment, hearing loss, secondary malignancies.
  • Post‑surgical complications – bile leaks, infections, and in transplant patients, graft rejection.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if your child experiences any of the following:
  • Sudden, severe abdominal pain or a rapidly enlarging abdominal mass.
  • Signs of internal bleeding: pale skin, dizziness, rapid heartbeat, or black/tarry stools.
  • Acute jaundice that develops over hours.
  • High fever (> 39 °C / 102 °F) with chills and worsening abdominal tenderness.
  • Sudden shortness of breath or coughing up blood (possible lung metastasis).
  • Severe vomiting that prevents keeping fluids down, leading to dehydration.

These symptoms may signal tumor rupture, infection, or treatment‑related complications that require urgent medical attention.

---

**References** (accessed May 2026)

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References